eTable 2. Recommendations for the Use of Symptomatic Treatments Commonly Prescribed for MS During Pregnancy and/or Breastfeeding

		Pregnancy		Breastfeeding		
		Use during	Recommendation	Use during	Recommendation	
Symptom	Drug	pregnancy	details	breastfeeding	details	
Depression and	Duloxetine ¹	Caution during	Data indicate that use in	May be used when	There are reports of	
anxiety		pregnancy ²	the month before delivery	breastfeeding1,2	sedation, poor feeding	
			may be associated with		and poor weight gain	
			an increased risk of		in infants exposed to	
			postpartum hemorrhage ¹		duloxetine through	
					breast milk1	
			Neonates exposed late in			
			the third trimester have		The developmental	
			developed complications		and health benefits of	
			requiring prolonged		breastfeeding should	
			hospitalization,		be considered	
			respiratory support, and		alongside the mother's	
			tube feeding ¹		clinical need for	
					duloxetine ¹	
			The risk of relapse when			
			discontinuing duloxetine			
			should be considered ¹			

		Pregnancy		Breastfeeding	
		Use during	Recommendation	Use during	Recommendation
Symptom	Drug	pregnancy	details	breastfeeding	details
Depression	Sertraline ³	May be used during	Studies in the first	May be used when	Data demonstrate low
		pregnancy ⁴	trimester highlight no	breastfeeding4	levels of sertraline and
			change in the major birth		its metabolites in
			defect risk vs background		human milk3
			rates ³		
			Exposure in the third		
			trimester may increase		
			the risk of persistent		
			pulmonary hypertension		
			and symptoms of poor		
			adaptation in the		
			neonate ³		
Fatigue	Amantadine ⁵	No during	Amantadine-related	No during	Amantadine is present
		pregnancy ⁵	complications during	breastfeeding ⁵	in breast milk and
			pregnancy have been		adverse drug reactions
			reported ⁵		have been reported in
					breastfed infants ⁵

		Pregnancy		Breastfeeding	
		Use during	Recommendation	Use during	Recommendation
Symptom	Drug	pregnancy	details	breastfeeding	details
Fatigue	Modafinil ⁶	Only if potential	There are no adequate	Caution during	It is not known whether
		benefit justifies	and well-controlled	breastfeeding ⁶	modafinil is present in
		potential risk to	studies of modafinil in		breast milk ^{6,8}
		fetus ^{6,7}	pregnant women ⁶		
					No adverse events are
			Intrauterine growth		known from the limited
			restriction and SA have		information available
			been reported in		on women who
			associated with		breastfed their infant
			modafinil ⁶		while receiving
					modafinil ^{6,8}
Mobility issues	Dalfampridine ⁹	No during	Adequate data on the	No during	There are no data
		pregnancy9,10	developmental risk	breastfeeding10	available on the
			associated with		presence of
			dalfampridine during		dalfampridine in breast
			pregnancy are not		milk or potential effects
			available ⁹		on breastfed infants ⁹
			Based on animal data,		
			may cause fetal harm9		

		Pregnancy		Breastfeeding	
		Use during	Recommendation	Use during	Recommendation
Symptom	Drug	pregnancy	details	breastfeeding	details
Mobility issues	Fampridine ¹¹	No during	Limited information ¹¹	No during	Limited information. It
		pregnancy ¹¹		breastfeeding11	is not known whether
			Animal studies have		fampridine is excreted
			demonstrated		in breast milk11
			reproductive toxicity ¹¹		
Muscle stiffness	Baclofen ¹²	No during	Adequate data on the	May be used when	Small amounts of
		pregnancy ¹³	developmental risk	breastfeeding12,13	baclofen have been
			associated with baclofen		detected in breast
			during pregnancy are not		milk ¹²
			available ¹²		
					Withdrawal symptoms
			Withdrawal symptoms		can occur in breastfed
			can occur in neonates		infants following
			whose mothers have		maternal
			been treated with oral		discontinuation or
			baclofen throughout		cessation of
			pregnancy ¹²		breastfeeding12
Muscle stiffness	Cyclobenzaprine ¹⁴	Only if clearly	No drug-associated risk	Caution when	No data are available
		needed ¹⁵	of major birth defects,	breastfeeding14,15	on cyclobenzaprine in
			miscarriage, or adverse		milk, effects on

		Pregnancy		Breastfeeding	
		Use during	Recommendation	Use during	Recommendation
Symptom	Drug	pregnancy	details	breastfeeding	details
			maternal or fetal		breastfed infants, or
			outcomes identified from		effects on milk
			case reports ¹⁴		production ¹⁴
Muscle stiffness	Tizanidine ¹⁶	Benefit should	Based on animal data,	Caution when	It is not known whether
		outweigh risk ^{16,17}	may cause fetal harm16	breastfeeding16	tizanidine is excreted
					in human milk16
Muscle	Intramuscular	Benefit should	In animal studies, there	Caution when	No data exist on the
stiffness/spasms	Botox ¹⁸	outweigh risk to the	were adverse effects on	breastfeeding18	use of botulin A during
		unborn fetus ¹⁸	fetal growth (decreased		breastfeeding, but
			fetal weight and skeletal		excretion into breast
			ossification) at clinically		milk is considered
			relevant doses, which		unlikely ^{18,19}
			were associated with		
			maternal toxicity18		
Pyelonephritis	Parenteral	May be used during	Use should be guided by	May be used when	Intravenous antibiotics
	antibiotic	pregnancy ²⁰	urine culture and	breastfeeding	are unlikely to be
	therapy ²⁰		sensitivity reports as	(recommendations for	passed on to babies in
			soon as available ⁷	individual antibiotics	sufficient amounts to
				should be followed) ²¹	cause issues via milk21

		Pregnancy		Breastfeeding	Breastfeeding	
		Use during	Recommendation	Use during	Recommendation	
Symptom	Drug	pregnancy	details	breastfeeding	details	
Seizures and	Gabapentin ²²	Benefit should	Adequate data on the	May be used when	Gabapentin passes	
neuropathic pain		outweigh risk to the	developmental risks for	breastfeeding ²³	into breast milk in	
		unborn fetus ²³	gabapentin in pregnancy		small amounts, but has	
			are not available ²²		not been known to	
					cause side effects in	
			Based on animal data,		breastfed infants ²³	
			may cause fetal harm ²²			
Seizures and	Carbamazepine ²⁴	Benefit should	Can cause fetal harm	No during	Carbamazepine and its	
neuropathic pain		outweigh risk to the	when administered to	breastfeeding ²⁴	epoxide metabolite are	
		unborn fetus ^{24,25}	pregnant women ²⁴		transferred into breast	
					milk and may cause	
					serious adverse events	
					in nursing infants ²⁴	
Seizures	Lamotrigine ²⁶	Benefits should	Data from prospective	May be used during	Lamotrigine is present	
		outweigh risk to the	exposure registries and	breastfeeding ²⁶	in breast milk ²⁶	
		unborn fetus ²⁷	epidemiological studies			
			of pregnant women have		Patients should	
			not detected an		monitor their children	
			increased frequency of		for potential adverse	
					events when	

		Pregnancy		Breastfeeding	
		Use during	Recommendation	Use during	Recommendation
Symptom	Drug	pregnancy	details	breastfeeding	details
			major congenital		breastfeeding while
			malformations ²⁶		receiving lamotrigine ²⁶
			Dose adjustments may		
			be necessary to maintain		
			clinical response ²⁶		
Seizures	Levetiracetam ²⁸	May be used during	Based on animal data,	May be used when	Levetiracetam may be
		pregnancy ²⁹	may cause fetal harm ²⁸	breastfeeding ^{28,29}	excreted in breast milk,
					but there are no data
			Plasma levels of		available on the effects
			levetiracetam may fall		of levetiracetam on
			during pregnancy,		breastfed infants ²⁸
			particularly during the		
			third trimester; dose		
			adjustments may be		
			necessary to maintain		
			clinical response ²⁸		
Seizures	Oxcarbazepine ³⁰	Benefit should	Plasma concentrations of	Caution during	Oxcarbazepine and its
		outweigh risk to the	the active metabolite of	breastfeeding31	active metabolite pass
		unborn ³¹	oxcarbazepine may fall		into breast milk, but

		Pregnancy			
		Use during	Recommendation	Use during	Recommendation
Symptom	Drug	pregnancy	details	breastfeeding	details
			during pregnancy;		their effects on
			pregnant patients should		breastfed infants and
			be monitored carefully30		milk production are
					unknown ³⁰
			There is a risk of seizures		
			in pregnant patients		
			receiving		
			oxcarbazepine ³⁰		
			Data from limited		
			pregnancies suggest that		
			use is associated with		
			congenital		
			malformations ³⁰		
Urinary	Solifenacin ³²	Benefit should	No information in	Caution when	No data are available
frequency and		outweigh risk to the	pregnant women	breastfeeding ³³	on solifenacin in milk
incontinence		unborn fetus ³³	available ³²		effects on breastfed
					infants, or effects on
					milk production ³²

		Pregnancy	Pregnancy		
		Use during	Recommendation	Use during	Recommendation
Symptom	Drug	pregnancy	details	breastfeeding	details
Urinary	Oxybutynin ³⁴	Benefit should	There are no adequate	Caution when	It is not known whether
incontinence		outweigh risk to the	and well-controlled	breastfeeding35	oxybutynin is excreted
		unborn fetus ³⁵	studies of oxybutynin in		in breast milk ³⁴
			pregnant women34		
Urinary tract	Amoxicillin ³⁶	Only if clearly	There are no adequate	Caution when	Penicillins are excreted
infection		needed ³⁶	and well-controlled	breastfeeding36	in human milk and may
			studies of amoxicillin in		lead to sensitization in
			pregnant women36		nursing infants36
Urinary tract	Cephalexin ³⁷	May be used during	There are no adequate	Caution when	Cephalexin is excreted
infection		pregnancy ³⁷	and well-controlled	breastfeeding37	in human milk ³⁷
			studies of cephalexin in		
			pregnant women37		
Urinary tract	Oral	May be used during	There are no adequate	Caution during	Trace amounts of
infection	nitrofurantoin38	pregnancy ³⁸	and well-controlled	breastfeeding38	nitrofurantoin have
			studies of oral		been detected in
			nitrofurantoin in pregnant		breast milk
			women ³⁸		
					There is potential for
					serious adverse events

		Pregnancy		Breastfeeding	
		Use during	Recommendation	Use during	Recommendation
Symptom	Drug	pregnancy	details	breastfeeding	details
					in nursing infants <1
					month of age38
Viral infection	Acyclovir ³⁹	Benefit should	There are no adequate	Caution when	Acyclovir has been
		outweigh risk to the	and well-controlled	breastfeeding ³⁹	documented in breast
		unborn fetus ³⁹	studies in pregnant		milk following oral
			women; however, a small		administration39
			registry study showed		
			that there was no		
			increased risk of birth		
			defects with acyclovir		
			exposure ³⁹		
Viral infection	Valacyclovir ⁴⁰	Benefit should	Decades of clinical trial	Caution when	There is no information
		outweigh risk to the	data have found no	breastfeeding40	on the presence of
		unborn fetus ⁴¹	association between		valacyclovir in breast
			valacyclovir or its		milk, but its metabolite,
			metabolite with major		acyclovir, is present in
			birth defects in pregnant		breast milk at levels
			women ⁴⁰		that would not be
					expected to cause side

		Pregnancy		Breastfeeding	
Symptom Drug		Use during pregnancy	Recommendation details	Use during	Recommendation details
	Drug			breastfeeding	
			Accumulating evidence		effects in breastfed
			from large pregnancy		infants ⁴⁰
			registries that oral		
			valacyclovir can be use	d	
			during pregnancy ⁴⁰		

Abbreviations: MS = multiple sclerosis; SA = spontaneous abortion.

- 1. Cymbalta [package insert]. Indianapolis, IN: Lilly USA, LLC; 2021.
- 2. National Health Service. Pregnancy, breastfeeding and fertility while taking duloxetine. Accessed March 3, 2023. https://www.nhs.uk/medicines/duloxetine/pregnancy-breastfeeding-and-fertility-while-taking-duloxetine/#:~:text=Duloxetine%20is%20not%20generally%20recommended,with%20your%20doctor%20or%20midwife
- 3. Sertraline hydrochloride [package insert]. Morristown, NJ: Almatica Pharma LLC; 2021.
- 4. National Health Service. Pregnancy, breastfeeding and fertility while taking sertraline. Accessed March 3, 2023. https://www.nhs.uk/medicines/sertraline/pregnancy-breastfeeding-and-fertility-while-taking-sertraline/#:~:text=Sertraline%20can%20be%20taken%20in,sertraline%20have%20a%20normal%20heart
- 5. Symmetrel [package insert]. Basel, Switzerland: Novartis Pharma AG; 2019.
- 6. Provigil [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2015.

- 7. Canibaño B, Deleu D, Mesraoua B, et al. Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations. J Drug Assess. 2020;9(1):20-36. doi:10.1080/21556660.2020.1721507
- 8. Modanifil. In: *Drugs and Lactation Database (LactMed®)*. National Institute of Child Health and Human Development; 2006-2023. Accessed March 9, 2023. https://www.ncbi.nlm.nih.gov/books/NBK513058/
- 9. Ampyra [package insert]. Pearl River, NY: Acorda Therapeutics, Inc.; 2022.
- Drugs.com. Dalfampridine pregnancy and breastfeeding warnings. Accessed March 3, 2023.
 https://www.drugs.com/pregnancy/dalfampridine.html
- 11. Fampyra [summary of product characteristics]. Accessed March 3, 2023. https://www.ema.europa.eu/en/documents/product-information/fampyra-epar-product-information_en.pdf
- 12. Ozobax [package insert]. Athens, GA: Metacel Pharmaceuticals, LLC; 2019.
- 13. National Health Service. Pregnancy, breastfeeding and fertility while taking baclofen. Accessed March 3, 2023. https://www.nhs.uk/medicines/baclofen/pregnancy-breastfeeding-and-fertility-while-taking-baclofen/
- 14. Amrix [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2019.
- 15. Drugs.com. Cyclobenzaprine pregnancy and breastfeeding warnings. Accessed March 3, 2023. https://www.drugs.com/pregnancy/cyclobenzaprine.html
- 16. Zanaflex [package insert]. Ardsley, NY: Acorda Therapeutics, Inc.; 2013.
- 17. Drugs.com. Tizanidine pregnancy and breastfeeding warnings. Accessed March 3, 2023. https://www.drugs.com/pregnancy/tizanidine.html

- 18. Botox [package insert]. Irvine, CA: Allergan, Inc.; 2011.
- 19. Botulin A. In: *Drugs and Lactation Database (LactMed®)*. National Institute of Child Health and Human Development; 2006-2023. Accessed March 9, 2023. https://www.ncbi.nlm.nih.gov/books/NBK501400/pdf/Bookshelf_NBK501400.pdf
- 20. National Institute for Health and Care Excellence. Pyelonephritis (acute): antimicrobial prescribing. Accessed March 3, 2023. https://www.nice.org.uk/guidance/ng111/resources/pyelonephritis-acute-antimicrobial-prescribing-pdf-66141593379781
- 21. Jones W, The Breastfeeding Network. Antibiotics and breastfeeding. Accessed March 3, 2023. https://www.breastfeedingnetwork.org.uk/antibiotics/
- 22. Neurontin [package insert]. New York, NY: Pfizer Inc; 2017.
- 23. National Health Service. Pregnancy, breastfeeding and fertility while taking gabapentin. Access March 3, 2023. https://www.nhs.uk/medicines/gabapentin/pregnancy-breastfeeding-and-fertility-while-taking-gabapentin/
- 24. Tegretol [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
- 25. National Health Service. Pregnancy, breastfeeding and fertility while taking carbamazepine. Accessed March 3, 2023.

 https://www.nhs.uk/medicines/carbamazepine/pregnancy-breastfeeding-and-fertility-while-takingcarbamazepine/#:~:text=Carbamazepine%20has%20been%20linked%20to,the%20medicine%20outweigh%20the%20risks
- 26. Lamictal [package insert]. Durham, NC: GlaxoSmithKline; 2023.
- 27. Drugs.com. Lamotrigine pregnancy and breastfeeding warnings. Accessed March 3, 2023. https://www.drugs.com/pregnancy/lamotrigine.html
- 28. Keppra [package insert]. Smyrna, GA: UCB, Inc.; 2019.

- 29. National Health Service. Pregnancy, breastfeeding and fertility while taking levetiracetam. Accessed March 3, 2023. https://www.nhs.uk/medicines/levetiracetam/pregnancy-breastfeeding-and-fertility-while-taking-levetiracetam/
- 30. Oxtellar XR [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.; 2018.
- 31. Drugs.com. Oxcarbazepine pregnancy and breastfeeding warnings. Accessed March 3, 2023. https://www.drugs.com/pregnancy/oxcarbazepine.html
- 32. Vesicare [package insert]. Northbrook, IL: Astellas Pharma Inc.; 2022.
- 33. Drugs.com. Solifenacin pregnancy and breastfeeding warnings. Accessed March 3, 2023. https://www.drugs.com/pregnancy/solifenacin.html
- 34. Ditropan XL [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2021.
- 35. Drugs.com. Oxybutynin pregnancy and breastfeeding warnings. Accessed March 3, 2023. https://www.drugs.com/pregnancy/oxybutynin.html
- 36. Amoxil [package insert]. Bristol, TN: Dr. Reddy's Laboratories Tennessee ILLC; 2015.
- 37. Keflex [package insert]. Locust Valley, NY: Fera Pharmaceuticals, LLC; 2018.
- 38. MacroBID [product monograph]. Accessed March 3, 2023. https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/macrobid-pm-eng-14aug2018.pdf
- 39. Zovirax [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005.
- 40. Valtrex [package insert]. Durham, NC: GlaxoSmithKline; 2022.

41. Drugs.com. Valacyclovir pregnancy and breastfeeding warnings. Accessed March 3, 2023.

https://www.drugs.com/pregnancy/valacyclovir.html